Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


MISCELLANEOUS (E.G., HYDROCARBONS, ETC.)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514789000MISCELLANEOUS (E.G., HYDROCARBONS, ETC.)89
20130072581Secreted Protein Acidic and Rich in Cysteine (SPARC) Protein SRM Assay - The current disclosure provides for specific peptides from the Secreted Protein Acidic and Rich in Cysteine (SPARC) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying SPARC directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. SPARC protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of SPARC peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.03-21-2013
20100076095METHOD AND APPARATUS FOR MITIGATING ACUTE REOXYGENATION INJURY DURING PERCUTANEOUS CORONARY INTERVENTION - A system and methods are described for improving the management of ischemic cardiac tissue during acute coronary syndromes. The system combines a catheter-based sub-system which allows for simultaneous balloon dilation of a coronary artery and infusion of a carefully controlled perfusate during percutaneous coronary intervention. The system allows for modulation of levels of oxygen at the time of percutaneous intervention. In addition, catheters and systems are provided for administration of fluids with modified oxygen content during an intervention that incorporate upstream flow control members to compartmentalize the perfusion of the target coronary artery and the remainder of the heart.03-25-2010
20120245235CLASSIFICATION OF CANCERS - A system for classifying a patient's cancer as belonging to one or more Cancer Modules of 1 of 15 different cancer types is provided. The Cancer Modules are useful to identify patient populations and individual patients demonstrating specific prognosis, risk of metastasis and/or recurrence, response or lack of response to drugs, and the like.09-27-2012
20130079425Urokinase-Type Plasminogen Activator Protein /Plasminogen Activator Inhibitor Type-1 Protein Selected Reaction Monitoring Assay - Specific peptides are provided that are derived from subsequences of the urokinase-type plasminogen activator protein and the plasminogen activator inhibitor type-1 protein along with assays that can measure those peptides directly in complex protein lysate samples, including protein lysates prepared from histologicaly-processed formalin fixed tissue. The presence and amount of those peptides in samples from a subject can be associated with disease, including cancer, in a subject and provide information about the diagnostic stage/grade/status of the disease/cancer.03-28-2013
20130079424METHODS FOR IDENTIFYING LEUKEMIA STEM CELLS AND DISTINGUISHING THEM FROM NORMAL HEMATOPIETIC STEM CELLS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: USES IN DIAGNOSIS, TREATMENT, AND RESEARCH - Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD3403-28-2013
20130079423DIAGNOSTIC METHODS INVOLVING LOSS OF HETEROZYGOSITY - The invention relates generally to methods of molecular analysis and particularly to methods of using genetic copy number variations and loss of heterozygosity in the characterization and treatment of disease.03-28-2013
20130035404Integrated Analyses of Breast and Colorectal Cancers - Genome-wide analysis of copy number changes in breast and colorectal tumors used approaches that can reliably detect homozygous deletions and amplifications. The number of genes altered by major copy number changes—deletion of all copies or amplification of at least twelve copies per cell—averaged thirteen per tumor. These data were integrated with previous mutation analyses of the Reference Sequence genes in these same tumor types to identify genes and cellular pathways affected by both copy number changes and point alterations. Pathways enriched for genetic alterations include those controlling cell adhesion, intracellular signaling, DNA topological change, and cell cycle control. These analyses provide an integrated view of copy number and sequencing alterations on a genome-wide scale and identify genes and pathways that are useful for cancer diagnosis and therapy.02-07-2013
20130041047Urinary Methylation Markers for Bladder Cancer - A method of detecting bladder cancer is described using hypermethylated urinary markers.02-14-2013
20090306230High Throughput Testing for Presence of Microorganisms in a Biological Sample - Provided are methods and apparatus for high throughput testing of biological samples that may or may not comprise microorganisms. The methods include the use of a diagnostic multiplexing panel (DMP) specifically designed for the simultaneous identification of a plurality of potential microorganisms that may be present in the biological sample via a primer extension reaction directed a highly conserved nucleic acid sequences in the microorganisms under test. The biological sample is typically immobilised on a solid substrate at a first location before being transferred to a second location for analysis using the DMP. The methods and apparatus of the invention are particularly suited to diagnosis of the presence of infectious pathogens in the biological sample, for example for diagnosis of sexually transmitted infection.12-10-2009
20130072582METHODS FOR DIAGNOSING AND TREATING ENCEPHALITIS OR EPILEPSY - The invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an antibody to LGI1. This invention further provides methods of treating an autoimmune encephalitis or an epilepsy, comprising the steps of detecting an antibody to LGI1 and treating a tumor associated with the disease.03-21-2013
20130072580USE OF URINARY NGAL TO DIAGNOSE SEPSIS IN VERY LOW BIRTH WEIGHT INFANTS - Methods for diagnosis of sepsis very low birth weight (VLBW) infants are disclosed. The diagnostic methods for sepsis are based on determining whether a bodily fluid sample, such as a urine sample, contains an amount of neutrophil gelatinase-associated lipocalin (NGAL) protein that exceeds or is less than a certain threshold level, or that falls within a certain range. The present invention also provides methods for monitoring the progression of sepsis, methods for monitoring sepsis treatment, methods of distinguishing between true-positive and false culture-positive sepsis, and kits for diagnosing sepsis in VLBW infants.03-21-2013
20130059930DIAGNOSTIC METHOD - The invention provides a method of detecting a subject suffering from, or at risk of suffering from, bladder cancer the method comprising 03-07-2013
20130059931ACTIVATION INDUCED DEAMINASE (AID) - The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide.03-07-2013
20130065972METHODS FOR SCREENING Th2 INFLAMMATORY DISEASES - The present invention provides a method for screening for a Th2 inflammatory disease in a subject comprising the steps of: assaying a miR-21 expression level in a biological sample from the subject, and comparing the miR-21 expression level in the biological sample from the subject to the miR-21 expression level in a control, wherein an increase in the miR-21 expression level in the biological sample from the subject compared to the miR-21 expression level in the control indicates the presence of Th2 inflammatory disease in the subject.03-14-2013
20080293830Method For Activating Efferent Sympathetic Nerves Innervating Adipose Tissues To Improve Obesity And Symptoms Associated Therewith - A method for activating an efferent sympathetic nerve innervating an adipose tissue and improving obesity-associated symptoms is provided, comprising stimulating an afferent vagal nerve from the liver without directly enhancing peroxisome proliferator-activated receptor (PPAR)-γ2 function in the liver.11-27-2008
20110086925Method and System to Detect, Diagnose, and Monitor the Progression of Alzheimer's Disease - Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of Alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate labeling the sample to identify at least one epigenetic marker; determining an amount of the at least one epigenetic marker; comparing the amount to a reference value; and determining a state of Alzheimer's disease.04-14-2011
20110269852METHODS AND MECHANISMS INVOLVING HYPERPIGMENTATION PARTICULARLY FOR AFRICAN AMERICAN SKIN - Sets of genes are identified that show modulated activity in hyperpigmented sun-exposed (HE) and non-hyperpigmented sun-exposed (NHE) skin, when compared to non-hyperpigmented non-exposed (NHNE) skin. The modulated sets of genes reveal important information about the genetic changes that take place in skin as a result of environmental exposure and damage. The modulated sets of genes may be used to fabricate custom DNA microarrays for evaluating patients with skin diseases or disorders. The microarrays may also be used to screen new substances for treating skin diseases and disorders. The modulated gene sets, and substances that target them, may also be used to develop therapies for individuals who suffer from hypopigmentation, such as those with Fitzpatrick type I skin or vitiligo.11-03-2011
20120295990Insulin Receptor Substrate 1 (IRS1) Protein SRM/MRM Assay - The current disclosure provides for specific peptides from the Insulin Receptor Substrate 1 (IRS1) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying IRS1 directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. IRS1 protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of IRS1 peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.11-22-2012
20080262108Method - The invention provides methods of screening test compounds for their ability to reduce retention of atherogenic lipoproteins in atherogenesis by measuring their activity as a modulator of the binding affinity of CEL (Carboxyl Ester Lipase) to various receptors. The invention further provides methods for the use of active modulators of the binding affinity of CEL to receptors for the prevention and treatment of atherosclerosis.10-23-2008
20110224313COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosing, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application.09-15-2011
20100210738PROGNOSTIC BIOMARKERS TO PREDICT OVERALL SURVIVAL AND METASTATIC DISEASE IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER - The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer. Likewise, in another example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANG, DICER1, EIF1, and MSH6. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of metastasis of TN breast cancer.08-19-2010
20100144903METHODS OF DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - In one embodiment, this invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of risk haplotypes in IL23R, IL17A, IL17RA and/or IL12RB1 locus. In another embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk haplotype at the IL12RB2 locus.06-10-2010
20130131194USE OF MICROVESICLES IN DIAGNOSIS AND PROGNOSIS OF MEDICAL DISEASES AND CONDITIONS - The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker in microvesicles isolated from a biological sample from the subject.05-23-2013
20130131195c-Src Selected Reaction Monitoring Assay - Objective quantitation of the c-Src protein directly in cancer patient tissue can aid in determining the aggressiveness of an individual patient's tumor as well as help make more informed decisions about choice of therapy. However, the c-Src protein is currently analyzed directly in formalin fixed patient tissue only by immunohistochemistry methodology which is at best subjectively semi-quantitative. This invention describes an objective quantitative assay for the c-Src protein using mass spectrometry as the analytical methodology. Specific peptides, experimentally discovered characteristics about the peptides, and experimentally established assay conditions based on those peptide characteristics are provided for use in a mass spectrometry-based Selected Reaction Monitoring (SRM) assay in order to measure relative or absolute quantitative levels of c-Src directly in a protein preparation obtained from a formalin fixed cancer patient tissue sample.05-23-2013
20110124744Magnetic Resonance-Based Viscometers and Methods - This invention relates generally to magnetic resonance (MR)-based methods and kits for measuring the viscosity of liquid samples.05-26-2011
20110086926Disabling thymus gland as a new method for treatment of multiple sclerosis - This invention is related to the treatment of the Multiple Sclerosis (MS).04-14-2011
20120035279PROTOCOL FOR SCREENING TRAVELERS - Methods for screening a traveler for an evaluation of the traveler's physical condition or health status by obtaining at least one specimen from the traveler and subjecting the specimen to at least one test that is diagnostic for at least one parameter of the physical condition or health status of the traveler prior to or while the traveler undertakes a journey. Thereafter, the results of the diagnostic test are reported prior to or contemporaneous with the arrival of the traveler at the traveler's destination.02-09-2012
20080255252Infectious Aetiology of Prostatic Disease and Methods to Identify Causative Agents - The present invention relates to a method of diagnosing, or predicting risk of, prostate disease in a subject. More particularly, the invention relates to a method of diagnosing the presence of, or the predisposition to develop, prostate disease in a subject, the method comprising analysing a test sample from the subject for the presence of 10-16-2008
20100280134Markers for Bladder Cancer Detection - A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The gene may be TWIST1 or a panel of genes such as TWIST1, NID2 and RUNX3 may be screened. The epigenetic change may be methylation. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises at least one primer pair for determining the methylation status of each of NID2, TWIST1 and RUNX3. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises means for detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. The kit also contains means for processing a urine sample.11-04-2010
20080242742Animal models of pancreatic adenocarcinoma and uses therefor - The present invention is based, at least in part, on the generation of an animal model of pancreatic adenocarcinoma which recapitulates the genetic and histological features of human pancreatic adenocarcinoma, including the initiation, maintenance, and progression of the disease. Accordingly, the present invention provides animal models of cancer, e.g., pancreatic adenocarcinoma, wherein an activating mutation of Kras has been introduced, and any one or more known or unknown tumor suppressor genes or loci, e.g., Ink4a/Arf, Ink4a, Arf, p53, Smad4/Dpc, Lkb1, Brca2, or Mlh1, have been misexpressed, e.g., have been misexpressed leading to decreased expression or non-expression. The animal models of the invention may be used, for example, to identify biomarkers of pancreatic cancer, to identify agents for the treatment or prevention of pancreatic cancer, and to evaluate the effectiveness of potential therapeutic agents.10-02-2008
20080214682METHODS OF TREATING PNEUMONIC PLAGUE - The present invention relates to methods of treating pneumonic plague. More specifically, the present invention relates to methods of using plasmin or Pla inhibitors to treat pneumonic plague.09-04-2008
20120302650Insulin-Like Growth Factor 1 Receptor (IGF1R) Protein SRM/MRM Assay - The current disclosure provides for specific peptides from the Insulin-Like Growth Factor 1 Receptor (IGF-1R) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying the IGF-1R directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. IGF-1R protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of an IGF-1R peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.11-29-2012
20120302649METHOD FOR SCREENING AMELIORANTS OF DRY SKIN CAUSED BY ATOPIC DERMATITIS USING BLEOMYCIN HYDROLASE ACTIVITY AS INDICATOR - The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.11-29-2012
20100324154ASSESSING SUSCEPTIBILITY TO VASCULAR DISORDERS - The invention provides methods and reagents for determination of risk and treatment of a vascular disorder such as abdominal aortic aneurysm (AAA) by detecting presence of gene polymorphisms and/or genetic profiles associated with an elevated or a reduced risk of the disorder. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of an individual which facilitate assessment of risk for developing such diseases.12-23-2010
20110152385NUCLEIC ACIDS AND METHODS FOR DETECTING TURFGRASS PATHOGENIC FUNGI - The present invention relates to the use of at least one nucleic acid comprising or consisting of: (i) CATCGAT-GAAGAACGCWGCRAAHTGCGATAMGTARTGYGAATTGCAGRATTCAGTGARTCATCGAAWYTTTGAACG-CAYMTTGCRC (SEQ ID NO: 1), wherein: R represents A or G Y represents C or T M represents A or C W represents A or T H represents A or C or T (ii) a portion of SEQ ID NO: 1, provided said nucleic acid binds under stringent conditions to a nucleic acid comprising or consisting of the complementary sequence of SEQ ID NO: 1, or (iii) complementary sequences of (i) and (ii); for the detection of nucleic acids from one or more fungi in a sample.06-23-2011
20110136922ACTIVATION INDUCED DEAMINASE (AID) - The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide.06-09-2011
20110218253IMAGING-BASED IDENTIFICATION OF A NEUROLOGICAL DISEASE OR A NEUROLOGICAL DISORDER - System(s) and method(s) are provided to enable imaging-based identification, detection, evaluation, and mapping of white matter microstructure and hemispheric organization of white matter in a central nervous system (CNS) structure afflicted by a neurological disease or disorder. Various embodiments exploit a set of diffusion tensor metrics to define a classification sub-space and determine a multivariate classifier through training data related to at least two groups of subjects: a first group of subjects afflicted by the neurological disease or neurological disorder, and a second group of subjects typically developing. The set of diffusion tensor metrics can be selected based at least on clinical information related to the neurological disease or neurological disorder and anatomy of CNS structure. Inclusion of tensor skewness asymmetry in such set yields an increase in sensitivity, specificity, accuracy, reliability, and predictive ability of the biological discrimination of subjects with and without a neurological disease or neurological disorder.09-08-2011
20090018218METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS - Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β01-15-2009
20090012186Mite Composition, Use Thereof, Method for Rearing the Phytoseiid Predatory Mite Amblyseius Sirskii, Rearing System for Rearing Said Phytoseiid Mite and Methods for Biological Pest Control on a Crop - The present invention relates to a novel mite composition comprising a population of the phytoseiid predatory mite species 01-08-2009
20120041082METHODS OF USING SMAD3 AND JAK2 GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE - Disclosed are methods of diagnosing Inflammatory Bowel Disease by determining the presence or absence of genetic variants at SMAD3 and/or JAK2 loci. Provided is a method of diagnosing a Crohn's Disease subtype in an individual by determining the presence or absence of a risk variant at the SMAD3 and/or JAK2 loci.02-16-2012
20120208899Tool for Assessment of Symptoms of Irritable Bowel Syndrome - Methods of treating and/or diagnosing irritable bowel syndrome (IBS) are provided, wherein treatment or diagnosis is undertaken on the basis of the patient's recordation of events associated with IBS in an event log and/or symptom diary.08-16-2012
20120208900METHODS OF PREDICTING THE NEED FOR SURGERY IN CROHN'S DISEASE - The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.08-16-2012
20120065277MICROFLUIDIC CHEMOSTAT - A chemostat is described that includes a growth chamber having a plurality of compartments. Each of the compartments may be fluidly isolated from the rest of the growth chamber by one or more actuatable valves. The chemostat may also include a nutrient supply-line to supply growth medium to the growth chamber, and an output port to remove fluids from the growth chamber. Also, a method of preventing biofilm formation in a growth chamber of a chemostat is described. The method may include the steps of adding a lysis agent to a isolated portion of the growth chamber, and reuniting the isolated portion with the rest of the growth chamber.03-15-2012
20110184073ASSAY - This invention relates to a method of detecting or determining the presence of prostate cancer cells in a sample of body fluid from a subject comprising: (i) isolating cells from said sample to provide a cell sample; (ii) contacting said cell sample with a specific binding member capable of binding a prostate antigen; and/or (iii) contacting said cell sample with a specific binding member capable of binding a minichromosome maintenance (MCM) polypeptide(s); and (iv) determining the binding of said specific binding member(s) to the cell sample.07-28-2011
20120149785METHOD OF ESTIMATING SEPSIS RISK IN AN INDIVIDUAL WITH INFECTION - A method of estimating sepsis risk in an individual with infection comprises a step of assaying a biological sample from the individual for an IL-2 or IL-7 mRNA value, and correlating the mRNA value with sepsis risk. The IL-2 and IL-7 mRNA values are quantified by absolute quantification of mRNA copy number, wherein the copy numbers are normalised to a house keeping gene and corrected against a calibration curve for serial dilutions of the IL-2 and IL-7 cDNA. The method generally involves a step of assaying a biological sample from the individual for IL-2 and/or IL-7 mRNA values, optionally in combination with mRNA values for other cytokines, and correlating a sum or difference of the values with sepsis risk using a regression analysis curve against outcome.06-14-2012
20120214880CANCER SCREENING BY DETECTION OF ULTRASTRUCTURAL AND MOLECULAR MARKERS - The present invention relates to detection of cancer, or assessment of risk of development thereof. In particular, the present invention provides compositions and methods detection of field carcinogenesis by identification of ultrastructural and molecular markers in a subject.08-23-2012
20120129957ANALYZING THE FMR1 GENE - A method of screening a human for risk of malignancies is disclosed. The method may include isolating the human's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, measuring the number of triple CGG repeats on each of the first and second alleles, wherein the measuring step is conducted through use of an assay, and identifying the human as at risk for cancer when the triple CGG repeat number for at least one of the first and second alleles is less than 26.05-24-2012
20130172431DIAGNOSTIC TEST - Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.07-04-2013
20120220672Presence of ERG Gene Rearrangements and Protein Over-expression in Low Grade PIN (LG-PIN) in Prostate Biopsies - The present disclosure relates to methods for the early detection of ERG over-expression, gene rearrangements, and diagnosis and/or prognosis of prostate cancer using a combined ERG IHC-FISH assay.08-30-2012
20120220671USE OF GALECTIN-3 FOR DETECTING AND PROGNOSING HEART FAILURE AFTER ACUTE CORONARY SYNDROME - The present invention relates to materials and methods for predicting the risk of heart failure in a subject with Acute Coronary Syndrome. The invention further relates to monitoring the efficacy of treatment for heart failure in a subject with Acute Coronary Syndrome.08-30-2012
20120259024POD FOR PROCESSING USED COOKING OILS AND PROCESSING APPARATUS - A pod for processing used cooking oils is disclosed that allows a higher energy efficiency of the process and better quality of the final result obtained, in view of different possible uses. This increase in terms of energy efficiency makes it possible to use an apparatus of the domestic appliance type, for processing a given quantity of used cooking oils together with the processing pod according to the invention. Providing the user with the possibility of opting among different combinations of functional substances provided in a main structure and in a secondary structure of the processing pod should, together with the possibility of using an apparatus of domestic use, allow the valorization of used cooking oils directly at the point of consumption.10-11-2012
20120252907DIAGNOSTIC METHODS AND KIT FOR DETECTING CANCER - The present disclosure is directed to compositions and methods for detecting elevated microRNA U6 concentrations in serum relative to a standard microRNA (e.g. SNORD44) as a diagnostic indicator of metastatic disease. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the risk of, breast cancer in an individual.10-04-2012
20120225955DETECTION OF AUTOANTIBODIES REACTIVE WITH PANCREATIC ISLET CELL ANTIGENIC MOLECULES AND/OR INSULIN - A method of screening a sample of body fluid obtained from an animal subject for analyte autoantibodies reactive with one or more antigenic molecules selected from pancreatic islet cell antigenic molecules (GAD, 1A2) and insulin, or one or more variants, analogues, derivatives or fragments thereof, and a kit for use in such a method. After addition of the sample one or more complexes comprising `antigenic molecule of fist source!-`analyte auto antibody!-`antigenic molecule of second source! The antigenic molecule of first source is immobilised to a solid phase, the second is labeled.09-06-2012
20120225954METHODS AND COMPOSITIONS FOR THE CLASSIFICATION OF NON-SMALL CELL LUNG CARCINOMA - The disclosure includes a method of screening for, diagnosing or detecting non-small cell lung carcinoma or an increased likelihood of developing non-small cell lung carcinoma in a subject. The method comprises: 09-06-2012
20120232170Cleaning composition having high self-adhesion and providing residual benefits - A composition for treating a hard surface. The composition has: (a) at least one adhesion promoter; (b) at least one surfactant selected from the group consisting of: anionic, non-ionic, cationic, amphoteric, zwitterionic, and combinations thereof; (c) mineral oil; (d) water; (e) optionally, at least one solvent; and wherein the composition is self-adhering upon application to a surface to be treated, and wherein the composition provides a wet film to said surface when water passes over said composition and surface.09-13-2012
20120270956USE OF PROTEIN SATB2 AS A MARKER FOR COLORECTAL CANCER - The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.10-25-2012
20110237688METHODS AND COMPOSITIONS RELATED TO ACETYLOCHOLINE RECEPTOR CONJUGATES - Disclosed are methods, compositions, and diagnostic kits for detecting acetylcholine receptor (AchR) autoreactive immune cells in a subject. The methods comprise detecting the binding of AChR-conjugate to penpheral blood AChR-specific B cells for diagnosing autoimmune disorders, including Myasthenia gravis (MG), systemic lupus erythematous (SLE), and rheumatoid arthritis (RA). More specifically, the detection is achieved by using flow cytometric assay with Alexa-conjugated AchR.09-29-2011
20120277326BIOMARKERS OF CANCER - Methods for diagnosis and staging of ovarian cancer, based on relative immunoreactivity of different IgG subclasses of autoantibodies, autoantibodies to defined antigens, e.g., antigens with specific subcellular localization, are described.11-01-2012
20120329886USE OF PERIOSTIN AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.12-27-2012
20130231404GENOME-PHENOME ANALYZER AND METHODS OF USING SAME - The present invention features methods, devices, and systems, e.g., for providing diagnostic or treatment decision support to a clinician for the diagnosis or treatment of a patient in need thereof or for diagnosing or treating a patient in need thereof.09-05-2013
20130012603METHODS FOR ASSESSING THE RISK OF CARDIOVASCULAR DISEASE - The studies described herein demonstrate that γ′ fibrinogen and total fibrinogen are independent risk factors for cardiovascular disease. Further described herein is the unexpected finding that an elevated concentration of γ′ fibrinogen in combination with an elevated concentration of total fibrinogen is a significantly better predictor of cardiovascular disease risk than either marker alone. Thus, provided herein are methods of detecting a subject having cardiovascular disease, or at increased risk of developing a cardiovascular disease, by measuring both the concentration of γ′ fibrinogen and the concentration of total fibrinogen in a sample obtained from the subject.01-10-2013
20130012602METHODS OF USING ZNF365 GENETIC VARIANTS TO DIAGNOSE CROHN'S DISEASE - The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the ZNF365 genetic locus01-10-2013
20130012604METHODS OF USING PRDM1 GENETIC VARIANTS TO PROGNOSE, DIAGNOSE AND TREAT INFLAMMATORY BOWEL DISEASE - Methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis are disclosed.01-10-2013
20080255253ANIMAL MODEL FOR PROSTATIC STROMAL HYPERPLASIA - The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under the skin or beneath the prostatic capsule of a non-human animal belonging to the species of the same as or different from the said animal. A substance effective for preventing/treating human benign prostatic hyperplasia can be screened by administering a test substance to the animal model and measuring the preventive or therapeutic effect of the test substance upon the implanted tissue (fetal urogenital sinus or tissue derived therefrom).10-16-2008
20130172430PROGNOSIS AND TREATMENT OF BREAST CANCER - Methods of prognosis and monitoring of breast cancer include determining the level of one or more of the markers comprising asymmetric dimethyl arginine (ADMA), beta-hydroxybutyrate (BHB) and microRNA-31 (miR-31) in patient samples. An increased level is correlated with poor prognosis. Breast cancer is treated by administration of one or more inhibitors of ADMA and/or BHB.07-04-2013
20080234393COMPOUNDS AND METHODS FOR DETECTION OF CARCINOMAS AND THEIR PRECURSOR LESIONS - The present invention relates to compounds and methods for detection and treatment of carcinomas and their precursor lesions. The invention provides DNase nucleic acids and polypeptides useful for the detection and treatment of carcinomas and their precursor lesions. The invention is more specifically related to a method for detection of carcinomas and their precursor lesions comprising the detection of the level and/or the subcellular localization of one or more DNase molecules in biological samples. Furthermore the present invention provides methods for early diagnosis, prognosis and monitoring of the disease course of carcinomas and their precursor lesions as well as for the treatment of said lesions.09-25-2008
20130178544METHOD FOR DIAGNOSIS AND MONITORING OF VIRAL INFECTION BY ANALYSIS OF VIRAL TRANSRENAL NUCLEIC ACIDS IN URINE - The present invention relates to methods for diagnosis or monitoring of viral infection by detecting the presence of transrenal viral nucleic acids or nucleic acids of viral origin in urine sample, with or without isolation of nucleic acids from a urine sample. The analysis of the nucleic acids is performed through hybridization of the nucleic acids with specific probes, or through a chain amplification reaction with specific primers. The methods are applicable to all viral pathogenic agents, including RNA, DNA, episomal, or integrated viruses.07-11-2013
20130178543BIOMARKER FOR DIAGNOSING CANCER AND METHOD OF ISOLATING CANCER CELL USING THE SAME - A method of detecting a cancer stem cell or circulating tumor cell that has undergone epithelial-mesenchymal transition, comprising determining the level of caveolin-1 expressed by a sample cell, and comparing the level of caveolin-1 expressed by the sample cell to a control, wherein higher expression of caveolin-1 by the sample cell indicates that the sample cell is a cancer cell, as well as a method of detecting cancer or metastasis in a subject, and related methods and compositions.07-11-2013
20080221225Genes associated with restenosis - The present invention identifies genes whose gene products are differentially expressed during restenosis, including de novo restenosis and in stent restenosis (ISR). Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to restenosis. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing restenosis.09-11-2008
20080221224UNIMOLECULAR TWEEZERS - Macromolecules may be specially designed so that upon adsorption at a substrate, the macromolecules experience intramolecular tension at their covalent bonds due to the physical interaction of the molecular segments of the macromolecules with the substrate. As a result of the induced tension, the macromolecules may be used in a number of applications including, but not limited to, environmental and surface sensors, chemical activators and catalysts, and molecular probes.09-11-2008
20080214681TASTE REDUCING COMPOSITIONS AND RELATED METHODS - A method includes contacting a surface in an oral cavity with a first composition capable of reducing a taste of a selected material, and orally administering a second composition separate from the first composition, the second composition including the selected material. The selected material can include a drug, and/or the second composition can further include a drug. In some embodiments, the first and second compositions are included in a kit.09-04-2008
20130096212Method and a Kit to Predict Response to Antidepressant Treatment - The present invention relates to the method for predicting the pharmacoresponse of antidepressants in patients diagnosed with major depression and panic disorder. According to the invention, SNP (rs41271330) in the coding region of the BMP5 gene together with the markers in linkage disequilibrium with this SNP could be used as predictors of SSRI treatment efficacy. The knowledge obtained by using the method disclosed in present invention has potential to increase the efficacy of pharmacological treatment in patients with major depression and panic disorder. The invention also provides a kit for detecting individual who are likely to respond to antidepressant treatment.04-18-2013
20130102692METHODS FOR ASSESSING RISK OF ALZHEIMER'S DISEASE IN A PATIENT - Disclosed are methods for diagnosis or prognosis of Alzheimer's disease in a patient. The methods may include assessing whether a patient has Alzheimer's disease or assessing a patient's risk for developing Alzheimer's disease. The methods typically include determining, either directly or indirectly, whether the patient has mutations, such as single nucleotide polymorphisms, in a plurality of genes that encode gene products that function in steroid biosynthesis.04-25-2013
20080200568Genes Associated With Type ll Diabetes Mellitus - Genes associated with Type II Diabetes Mellitus (T2DM) are identified and screening methods to identify chemical compounds that act on those targets for the treatment of T2DM or its associated pathologies are discussed. The use of EP3 antagonist was found to affect blood glucose levels in mice fed a high-fat diet and made insulin deficient by streptozocin injection.08-21-2008
20080200567IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS - A transgenic non-human animal, in particular a transgenic mouse, encoding Qpct proteins which have been implicated in Qpct-related diseases. Also disclosed are cells and cell lines comprising transgenes encoding for Qpct. Further disclosed are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.08-21-2008
20080200566Dephosphorylation of HDAC7 By Myosin Phosphatase - The present invention relates to screening methods that make use of a histone deacetylase interacting with a myosin phosphatase for the identification of novel therapeutics useful for inhibiting or inducing apoptosis and for the treatment of pathological conditions, such as smooth muscle cell disorder, cardiac hypertrophy or asthma. Also disclosed are methods for inhibiting or inducing apoptosis and for treatment of a pathological condition by administering to a mammal a therapeutically effective amount of a compound that inhibits or increases the dephosphorylation of a histone deacetylase by a myosin phosphatase or inhibits or increases the binding of a histone deacetylase to a myosin phosphatase.08-21-2008
20110230571DIAGNOSTIC AND THERAPEUTIC PROTOCOLS - The present invention relates to methods for determining co-receptor usage of an HIV in a subject including the steps of: culturing a viral preparation derived from the subject's plasma with one or more cell lines which express surface CD4 and CCR5, surface CD4 and CXCR4, or surface CD4, CCR5 and CXCR4, wherein an anticoagulant is added to the viral preparation or to the culture; and screening for infection, wherein the presence or absence of infected cells is indicative of the co-receptors used by the HIV.09-22-2011
20100286291MULTIPLEX DETECTION OF HEPATITIS VIRUS VARIATIONS - Disclosed is a method for the detection of virus variations. Disclosed also is a method for the treatment of virus infection in a subject based on the detection of virus variations. Additionally, a kit is provided for the detection of virus variations.11-11-2010
20100286290ENZYME ACTIVITY ASSAY USING ROLLING CIRCLE AMPLIFICATION - The present invention relates to an enzyme activity assay using rolling circle amplification for verifying that a sample contains the enzyme activity in question. Thus, the present invention pertains to a method for determining the presence or absence of one or more enzyme activities involved in circularising a non-circular oligonucleotide probe in a biological sample. Furthermore, the present invention concerns liquid compositions comprising one or more oligonucleotide probes. Within the scope of the present invention is also a composition comprising a liquid composition and a tissue sample, and solid support of one or more oligonucleotides of the present invention. Disclosed is also a microfluidic device with one or more compartments for performing rolling circle amplification events, and a method for correlating one or more rolling circle amplification events. Methods for testing the efficacy of a drug, for diagnosing or prognosing a disease, for treating a disease, or for treating prophylactically a disease is furthermore disclosed.11-11-2010
20130150465PIG MODEL FOR BREAST CANCER, MITOCHONDRIA RELATED PROTEIN FOLDING DISORDERS AND/OR EPIDERMOLYSIS BULLOSA SIMPLEX - The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed.06-13-2013
20100292348DETECTION OF METHYLATED DNA AND DNA MUTATIONS - The present invention relates to various methods of detecting DNA methylation and defected DNA. In one embodiment, the invention provides a nanosensor bound to a probe that is complementary to a DNA methylation sequence.11-18-2010
20080262109METHOD FOR PRODUCING LIQUID PREPARATIONS HAVING A SOLID BODY CONTENT - A method for producing a liquid preparation having a solid body content and the resulting liquid preparation. According to the method, the addition of at least a portion of the solid bodies takes place only (a) in the last stage of the method preceding the pouring of the liquid preparation into a packing unit or (b) during the pouring into a packing unit.10-23-2008
20110313058METHOD AND APPARATUS FOR LIMITING GROWTH OF EYE LENGTH - Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders.12-22-2011
20130245135METHODS AND COMPOSITIONS FOR ASSESSING PATIENTS WITH PREECLAMPSIA-RELATED CONDITIONS USING MICRORNA - The invention is directed to methods and compositions for collecting a non-placental biological samples of cells and quantifying and comparing levels of expression of microRNAs to characterize a preeclampsia-related condition. The samples may be collected before or after an intervention or may be collected over a period of time. One of the samples may be a control sample. Patients may then be treated according to their response.09-19-2013
20130197106METHODS OF IDENTIFYING A CANDIDATE COMPOUND - The invention relates to methods identifying compounds for the treatment of cell proliferation-related disorders, e.g., proliferative disorders such as cancer.08-01-2013
20130203870Animal Models of Atherosclerosis - The present invention provides transgenic, large non-human animal models of atherosclerosis and hypercholesterolemia, as well as methods of using such animal models in the identification and characterization of therapies for atherosclerosis and hypercholesterolemia.08-08-2013
20130203871FUIDI HERD MANAGEMENT SCHEMA - The invention is a herd management schema based upon the inventor's analysis of the natural history of bovine infection due to 08-08-2013
20120095117GALECTIN-3 nsSNP MARKER FOR CANCER - A diagnostic biomarker including a mechanism for determining a patient's propensity to develop cancer. A diagnostic kit for determining a patient's propensity to develop cancer. A method of predicting both a patient's and a population's propensity to develop cancer, by detecting the presence of an H04-19-2012
20120095116PROBE SET FOR IDENTIFICATION OF NUCLEOTIDE MUTATION, AND METHOD FOR IDENTIFICATION OF NUCLEOTIDE MUTATION - A probe set comprising a detection probe and a counter probe, wherein the detection probe comprises an oligonucleotide which comprises a nucleotide sequence containing the mutation site on the target nucleic acid and also containing a nucleotide of interest in the mutation site or a nucleotide sequence complementary to the aforementioned nucleotide sequence, has a fluorescent substance added to the 5′-terminal and a quenching substance added to the 3′-terminal, and has, introduced therein, such a modification that the melting temperature of the probe becomes 3° C. or more higher than that of the counter probe, and wherein the counter probe comprises an oligonucleotide which comprises a nucleotide sequence containing a mutation site and also containing a nucleotide that is different from the nucleotide of interest in the mutation site or a nucleotide sequence complementary to the aforementioned nucleotide sequence.04-19-2012

Patent applications in class MISCELLANEOUS (E.G., HYDROCARBONS, ETC.)